Filing Flows › Coya Therapeutics (COYA) › Q4 2024
Coya Therapeutics (COYA) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 18, 2025
Coya Therapeutics (COYA) reported revenue of $2K for the fourth quarter 2024 (Q4 2024), -100% from a year earlier.
Coya Therapeutics, Q4 2024: revenue $2K (-100% year over year), net loss $2.9M, operating cash flow −$2.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2K | — | -100% |
| Operating profit | −$4.1M | — | — |
| Net earnings | −$2.9M | — | — |
| Operating cash flow | −$2.4M | — | — |
What changed
Revenue was $2K in Q4 2024, down 100% year over year.
Operating costs exceeded revenue by $4.1M, an operating margin of -209031.5%. Total costs fell 3% while revenue fell 100%. The fastest-growing cost line was Research & development (+20%). The quarter ended with a net loss of $2.9M. Non-operating items added $1.2M, -40% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$2.4M. Non-cash charges added back $7K of depreciation and $791K of share-based compensation. Working capital and other items used $291K.
Questions
What was Coya Therapeutics' revenue in the fourth quarter 2024?
Coya Therapeutics (COYA) reported revenue of $2K for the fourth quarter 2024 (Q4 2024), -100% from a year earlier.
Source: Coya Therapeutics 10-K on SEC EDGAR.